文献速递核素与放射性配体治疗肿瘤 PET/CT

初治前列腺癌 upfront 使用 177Lu-PSMA 放射性配体治疗及疗效评估

Upfront Use of 177Lu-Labeled PSMA Radioligand Therapy and Treatment Response Assessment in Treatment-Naive Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2022-01-01

本文报道一例寡转移性前列腺癌患者,未经雄激素剥夺治疗(ADT)即接受 177Lu 标记 PSMA 放射性配体治疗,单剂 177Lu-PSMA-617 后显示极佳疗效。文章指出 ADT 虽为转移性前列腺癌标准治疗但不良反应显著,因此推迟 ADT 并实现良好无进展生存的治疗策略受到关注。

要点

  • 寡转移性前列腺癌可考虑 upfront 177Lu-PSMA-617 治疗以推迟 ADT。
  • 单剂 177Lu-PSMA-617 在该例中显示极佳治疗反应。
  • 需权衡推迟 ADT 与维持无进展生存的临床获益。

核心结论

  • 初治寡转移性前列腺癌 upfront 使用 177Lu-PSMA-617 单剂治疗显示极佳反应,提示该策略可能推迟 ADT。

研究设计与样本

  • 个案报道,对象为一例寡转移性前列腺癌初治患者。

主要发现

  • 该患者接受 upfront 177Lu 标记 PSMA 放射性配体治疗,单剂 177Lu-PSMA-617 后显示极佳治疗反应。

临床怎么用

  • 对寡转移性前列腺癌初治患者,可探索 upfront 177Lu-PSMA-617 以推迟 ADT 并维持无进展生存。

局限性

  • 仅为单例个案报道,证据等级有限,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostatic malignancy is the most common type of nonskin cancer and associated with significant morbidity and mortality. Early androgen deprivation therapy (ADT) is the treatment of choice in metastatic prostate cancer, whereas ADT delays progression of disease, but it is associated with significant adverse effects and frequently impairs the quality of life. Therefore, there is growing interest in treatments to postpone ADT while achieving a good progression-free survival. We present a case of oligometastatic prostate cancer, who was treated upfront with 177Lu-labeled PSMA radioligand therapy and demonstrated excellent response to a single dose of 177Lu-PSMA-617.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Malik D, Sen IB, Thakral P, et al. Upfront Use of 177Lu-Labeled PSMA Radioligand Therapy and Treatment Response Assessment in Treatment-Naive Prostate Cancer. Clin Nucl Med. 2022. PMID: 34524171. doi:10.1097/RLU.0000000000003890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。